Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas and the Western Pacific region

Winokur, PL; Canton, R; Casellas, JM; Legakis, N

dc.contributor.author	Winokur, PL	en
dc.contributor.author	Canton, R	en
dc.contributor.author	Casellas, JM	en
dc.contributor.author	Legakis, N	en
dc.date.accessioned	2014-03-01T01:51:24Z
dc.date.available	2014-03-01T01:51:24Z
dc.date.issued	2001	en
dc.identifier.issn	1058-4838	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/26277
dc.subject.classification	Immunology	en
dc.subject.classification	Industrial Relations & Labor	en
dc.subject.classification	Infectious Diseases	en
dc.subject.classification	Microbiology	en
dc.subject.other	RESISTANT KLEBSIELLA-PNEUMONIAE	en
dc.subject.other	ESCHERICHIA-COLI	en
dc.subject.other	FAMILY ENTEROBACTERIACEAE	en
dc.subject.other	SUSCEPTIBILITY PATTERNS	en
dc.subject.other	PSEUDOMONAS-AERUGINOSA	en
dc.subject.other	MEMBERS	en
dc.subject.other	SYSTEM	en
dc.title	Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas and the Western Pacific region	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2001	en
heal.abstract	To evaluate the prevalence of extended-spectrum beta -lactamase (ESBL)-producing strains among species of Enterobacteriaceae, a microdilution susceptibility test was performed with strains of Klebsiella pneumoniae, Escherichia coli, Proteus mirabilis, and Salmonella species that were isolated as part of the SENTRY project. The highest percentage of ESBL phenotype (defined as a minimum inhibitory concentration [MIC] greater than or equal to2 mug/mL for ceftazidime, ceftriaxone, or aztreonam) was detected among K. pneumoniae strains from Latin America (45%), followed by those from the Western Pacific region (25%), Europe (23%), the United States (8%), and Canada (5%). P. mirabilis and E. coli strains for which MICs of extended-spectrum cephalosporins or monobactams were elevated also were more prominent in Latin America. Testing with ceftazidime revealed more isolates with elevated MICs than did testing with ceftriaxone or aztreonam. ESBL strains showed high levels of co-resistance to aminoglycosides, tetracycline, trimethoprim-sulfamethoxazole, and ciprofloxacin. Imipenem remains highly effective against ESBL strains. Organisms expressing an ESBL are widely distributed worldwide, although prevalence rates are significantly higher in certain geographic regions.	en
heal.publisher	UNIV CHICAGO PRESS	en
heal.journalName	CLINICAL INFECTIOUS DISEASES	en
dc.identifier.isi	ISI:000168311200002	en
dc.identifier.volume	32	en
dc.identifier.spage	S94	en
dc.identifier.epage	S103	en